Clinical trials
Advance Solid Tumors clinical trials
Below are recruiting advance solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,386 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07098052RecruitingPhase 1
Study of HDM2020 for advanced solid tumors
This trial is testing a new drug called HDM2020 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07487597RecruitingEarly Phase 1
Engineered T cell therapy for ALPP-positive advanced solid tumors
This trial tests a new type of immune cell therapy designed to target and attack cancer cells that have a specific marker called ALPP. It is for people with advanced solid tumors who have not responded to or cannot have standard treatments.
Nanjing, JiangsuAges 18–70 - NCT06404905RecruitingPhase 1
Testing BT02 for advanced solid tumors
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
Beijing, BiejingAges 18–75 - NCT06394622RecruitingPhase 1
CAR-NKT cells targeting CD70 for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments and whose tumors are CD70-positive.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06596473RecruitingPhase 1
Study of BG-C477 for advanced solid tumors
This trial tests a new drug called BG-C477 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
Goodyear, ArizonaAges 18 years+ - NCT06245122RecruitingPhase 1
Study of CS23546 for advanced tumors
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
GuangzhouAges 18 years+ - NCT07469982RecruitingPhase 1
Study of SY-9453 for advanced solid tumors
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
ShanghaiAges 18 years+ - NCT06350006RecruitingPhase 1
Testing SHR-A1904 combinations for CLDN18.2-positive advanced tumors
This study tests an experimental drug combination for people with advanced solid tumors that have a specific protein called CLDN18.2. It aims to see if the combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06214143RecruitingPhase 1/Phase 2
T3011 plus immunotherapy for advanced solid tumors
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
AnyangAges 18 years+ - NCT06332170RecruitingPhase 1
HS-20093 combination safety study for advanced solid tumors
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06990464RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial is testing an investigational drug called SIBP-A19 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Fuzhou, FujianAges 18–75 - NCT07299747RecruitingPhase 1/Phase 2
Study of VBC103 for advanced solid tumors
This trial tests a new drug, VBC103, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink or slow the growth of these tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06170294RecruitingPhase 1
MAGE-A4 TCR-T therapy for advanced solid tumors
This trial tests a new type of immune therapy called MAGE-A4-directed TCR-T. It uses your own immune cells (T cells) that are modified to find and attack cancer cells that have a specific protein (MAGE-A4). It is for people with advanced solid tumors who have already tried other treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06173219RecruitingPhase 1/Phase 2
Radiation and immunotherapy for advanced cancer
This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT07069062RecruitingPhase 1/Phase 2
Study of HY0001a for Advanced Solid Tumors
This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06143774RecruitingPhase 1
Study of TRX-920 for advanced solid tumors
This trial tests a new drug called TRX-920 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if TRX-920 is safe and effective.
TaichungAges 18–100 - NCT06126666RecruitingPhase 1
ABL103 for advanced solid tumors
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Seongnam, SeoulAges 18 years+ - NCT06619587RecruitingPhase 1
Study of GDC-7035 for advanced solid tumors with KRAS G12D
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06094556RecruitingPhase 1
A study of SHR-1826 for advanced solid tumors
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT05835609RecruitingPhase 1
PM534 IV treatment for advanced solid tumors
This early-phase study tests PM534 given through an IV to see if it is safe and how well it works in people with advanced solid tumors. It may help by finding a new treatment option, but eligibility is strict to protect participants from side effects.
BarcelonaAges 18 years+ - NCT07601243RecruitingPhase 1
GS-2426 for advanced solid tumors with MTAP deficiency
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
Grand Rapids, MichiganAges 18 years+ - NCT06428331RecruitingPhase 1
Study of SKB518 for advanced solid tumors
This trial tests a new drug called SKB518 for people with advanced solid tumors that have stopped responding to standard treatments or cannot receive them. The goal is to see if SKB518 can help shrink or control the tumor.
Shanghai, ChinaAges 18 years+ - NCT07251166RecruitingPhase 1
Safety study of GenSci140 for advanced solid tumors
This trial tests a new drug, GenSci140, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
Shenyang, LiaoningAges 18–75 - NCT06404528Recruiting
Low-dose chemo under low blood sugar for advanced solid tumors
This trial tests whether giving low-dose chemotherapy while your blood sugar is low can help treat advanced solid tumors that have stopped responding to standard treatments. It aims to see if this approach is safe and effective.
Wuxi, JiangsuAges 18–75
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advance solid tumors?
- Yes. Clin2 currently lists 1,386 recruiting advance solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advance solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advance solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.